Hepatic reactions usually occur in the early weeks of treatment, but may happen at any time in the six month standard treatment period. Although hepatic reactions are usually due to a single drug, a recent case report'5 shows that occasionally a combination of drugs which individually cause no problem may cause hepatitis, a phenomenon originally reported in 1975.16 Jaundice is usually preceded by a period of days or weeks of malaise or nausea.
There is clearly a requirement to balance the need for full compliance with treatment -which is the major factor in outcome'7 and is essential to prevent the emergence of drug resistance -with the risk of the patient and/or doctor continuing the medication when the patient has become unwell or has symptoms consistent with hepatitis.
Mitchell et al'8 have recently described four of the 243 cases of hepatotoxicity to antituberculosis drugs reported to the CSM. From the limited information given in the cases described, which did not include patient weights or drug dosages, none of the four cases was managed as advised in the Joint Tuberculosis Committee treatment guidelines,3 and it is not stated whether the drug therapy was being supervised by a thoracic physician or other appropriately experienced physician. Their paper attempted no risk/benefit analysis of antituberculosis drugs, and did not mention the significant death rate from tuberculosis as discussed earlier in this editorial. The risks of the disease itself, or of inadequate treatment, are clearly many times higher than the risks from currently recommended treatment regimens. One of their recommendations was that rifampicin and isoniazid should be stopped if the level of hepatic transaminases rose to three times the normal value or the bilirubin level was raised, but they did not suggest that treatment with pyrazinamide, which is also potentially hepatotoxic, should be discontinued, nor did they address the problem of cases of tuberculosis -who may or may not be infectious from examination of their sputum -who had abnormal liver function before treatment to the levels that they were suggesting. Since pretreatment liver function abnormalities are not uncommon in tuberculosis,'9 patients may be denied necessary treatment, substantially increasing both the morbidity and mortality from their tuberculosis. Finally, they suggested alternative drug treatment with, for example, ciprofloxacin and streptomycin in patients after liver transplantation, which is not evidentially based and did not specify what they meant by "prolonged".
After consideration of all the factors including recent publications, we offer the following recommendations on behalf of the Joint Tuberculosis Committee which update the relevant section in the 1990 treatment guidelines.3
(1) All tuberculosis patients should have pretreatment measurements of liver function.3
(2) Standard drug treatment should be given under the supervision of a respiratory or other suitably qualified physician.3
(3) All patients should be advised and informed of possible side effects, as should their general practitioner. This may be done by simple written information in English and the patient's own language, perhaps supplemented by access to a named health visitor. Instructions should be explicit as to the indications for stopping medication and seeking advice -that is, persistent nausea, vomiting, malaise, or jaundice.
(4) Regular monitoring of liver function is required in patients with known chronic liver disease -for example, alcohol, chronic active hepatitis, cirrhosis, and in those known to be hepatitis B or C antigen positive. Surveillance should be particularly frequent in the first two months of treatment with weekly liver function tests in the first two weeks, and then at two week intervals.
(5) If the patient has no evidence of pre-existing liver disease and normal pretreatment liver function, liver function need only be repeated (and treatment stopped) iffever, malaise, vomiting, jaundice, or unexplained deterioration during treatment occur. The possibility of coexisting acute viral hepatitis should be considered20 and appropriate virology tests performed if indicated.
(6) Modest elevations of aspartate transaminase (AST) and alanine transaminase (ALT) are not uncommon in the pretreatment liver function tests of tuberculosis patients, or immediately after the introduction of treatment. '" If the AST/ALT levels are two or more times above normal, liver function should be monitored weekly for two weeks and then two weekly until normal. If the ALT/AST levels are just under twice the normal values, the liver function should be repeated after two weeks. If the transaminase levels have fallen, further repeat tests are then only required for symptoms. If the repeat tests show that ALT/AST levels have risen to more than twice the normal values, management should be as above. If the AST/ALT level rises to five times normal or the bilirubin level rises, rifampicin/isoniazid/pyrazinamide should be stopped.2' (7) What happens next depends on the circumstances: (a) Ifthe patient is not unwell, and the form oftuberculosis is non-infectious,22 no treatment need be given until liver function returns to normal. (b) If the patient is clinically unwell or the sputum is smear positive within two weeks of commencing treatment, then some form of drug therapy needs to be given, preferably as an inpatient, until liver function is normal. Streptomycin and ethambutol, with appropriate checks on renal function3 and visual acuity, should be used unless there is clinical suspicion or bacteriological evidence of resistance to these drugs. It may sometimes be better to interrupt treatment unless this is felt to be prejudicial to survival. If alternative medication is necessary, an individually tailored drug combination to which the organism is -or is thought likely to be -sensitive may be needed. This may have to include reserve drugs3 when the potential hepatoxicity of ethionamide/prothionamide and macrolides needs to be considered. (c) Once liver function is normal challenge dosages of the original drugs can be reintroduced sequentially in the order isoniazid, rifampicin, and pyrazinamide24 with daily monitoring of the patient's clinical condition and liver function. Isoniazid should be introduced initially at 50 mg/ day, increasing sequentially to 300 mg/day after 2-3 days if no reaction occurs, and then continued. After a further 2-3 days without reaction rifampicin at a dose of 75 mg/ day can be added, increasing to 300 mg after 2-3 days, and then to 450 mg (<50 kg) or 600 mg (>50 kg) as appropriate for the patient's weight after a further 2-3 days without reaction, and then continued. Finally, pyrazinamide is added at 250 mg/day, increasing to 1000mg after 2-3 days and then to 1500 mg (<50 kg) or 2000 mg (>50 kg). (8) Ifthere is no further reaction standard chemotherapy can be continued and any alternative drugs introduced temporarily can then be withdrawn.
(9) If there is a further reaction the offending drug should be excluded and a suitable alternative regimen used. Such an alternative regimen should be on the advice of, and under the supervision of, a respiratory physician.3 If pyrazinamide is found to be the offending drug, treatment will need to be continued for nine months with rifampicin and isoniazid, supplemented by ethambutol for the initial two months.3 (10) Occasionally the choice of alternative drugs is so limited -for example, by drug-resistant organisms -that desensitisation and reintroduction of the offending drug may be necessary using conventional protocols. 25 To avoid the emergence of drug resistance during desensitisation the procedure must be carried out under the cover of two other antituberculosis drugs. 
